Bendamustine Hydrochloride Monohydrate is a benzimidazole-class alkylating agent used primarily in the treatment of chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. By functioning as… Read more
Bendamustine Hydrochloride Monohydrate is a benzimidazole-class alkylating agent used primarily in the treatment of chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. By functioning as an antineoplastic agent that cross-links DNA to inhibit cell division in malignant hematopoietic cells, this medication requires rigorous quality control throughout its manufacturing and distribution. Analytical laboratories rely on high-quality reference standards of the active pharmaceutical ingredient, along with its related pharmacopeial and non-pharmacopeial impurities, to support precise testing. The inclusion of metabolites and stable isotope labelled compounds in this category enables accurate identification and quantification, which are essential for comprehensive impurity profiling and method validation. These research materials ensure that pharmaceutical testing protocols consistently meet the necessary regulatory standards for purity and safety during the development and stability analysis of this critical oncology treatment.